Evolocumab Safe and Effective in Pediatric FH

The PCSK9 inhibitor lowered LDL cholesterol by 38% vs placebo in HAUSER-RCT, the first randomized controlled trial of one of these agents in the pediatric population.
Medscape Medical News

Source link